QQQ   310.67 (+3.24%)
AAPL   150.00 (+3.14%)
MSFT   260.97 (+3.25%)
META   190.56 (+24.45%)
GOOGL   107.17 (+6.71%)
AMZN   111.24 (+5.79%)
TSLA   193.66 (+6.75%)
NVDA   212.44 (+1.44%)
NIO   12.23 (+1.07%)
BABA   108.98 (-3.40%)
AMD   87.02 (+2.81%)
T   20.42 (+1.19%)
MU   62.15 (-0.72%)
F   14.51 (+5.22%)
CGC   3.12 (+1.30%)
GE   82.69 (+0.45%)
DIS   112.54 (+2.88%)
AMC   6.26 (+9.63%)
PFE   44.18 (+0.48%)
PYPL   87.81 (+5.91%)
NFLX   367.45 (+1.51%)
QQQ   310.67 (+3.24%)
AAPL   150.00 (+3.14%)
MSFT   260.97 (+3.25%)
META   190.56 (+24.45%)
GOOGL   107.17 (+6.71%)
AMZN   111.24 (+5.79%)
TSLA   193.66 (+6.75%)
NVDA   212.44 (+1.44%)
NIO   12.23 (+1.07%)
BABA   108.98 (-3.40%)
AMD   87.02 (+2.81%)
T   20.42 (+1.19%)
MU   62.15 (-0.72%)
F   14.51 (+5.22%)
CGC   3.12 (+1.30%)
GE   82.69 (+0.45%)
DIS   112.54 (+2.88%)
AMC   6.26 (+9.63%)
PFE   44.18 (+0.48%)
PYPL   87.81 (+5.91%)
NFLX   367.45 (+1.51%)
QQQ   310.67 (+3.24%)
AAPL   150.00 (+3.14%)
MSFT   260.97 (+3.25%)
META   190.56 (+24.45%)
GOOGL   107.17 (+6.71%)
AMZN   111.24 (+5.79%)
TSLA   193.66 (+6.75%)
NVDA   212.44 (+1.44%)
NIO   12.23 (+1.07%)
BABA   108.98 (-3.40%)
AMD   87.02 (+2.81%)
T   20.42 (+1.19%)
MU   62.15 (-0.72%)
F   14.51 (+5.22%)
CGC   3.12 (+1.30%)
GE   82.69 (+0.45%)
DIS   112.54 (+2.88%)
AMC   6.26 (+9.63%)
PFE   44.18 (+0.48%)
PYPL   87.81 (+5.91%)
NFLX   367.45 (+1.51%)
QQQ   310.67 (+3.24%)
AAPL   150.00 (+3.14%)
MSFT   260.97 (+3.25%)
META   190.56 (+24.45%)
GOOGL   107.17 (+6.71%)
AMZN   111.24 (+5.79%)
TSLA   193.66 (+6.75%)
NVDA   212.44 (+1.44%)
NIO   12.23 (+1.07%)
BABA   108.98 (-3.40%)
AMD   87.02 (+2.81%)
T   20.42 (+1.19%)
MU   62.15 (-0.72%)
F   14.51 (+5.22%)
CGC   3.12 (+1.30%)
GE   82.69 (+0.45%)
DIS   112.54 (+2.88%)
AMC   6.26 (+9.63%)
PFE   44.18 (+0.48%)
PYPL   87.81 (+5.91%)
NFLX   367.45 (+1.51%)
NASDAQ:AKBA

Akebia Therapeutics - AKBA Stock Forecast, Price & News

$0.86
+0.19 (+28.49%)
(As of 02/2/2023 11:53 AM ET)
Add
Compare
Today's Range
$0.73
$0.90
50-Day Range
$0.25
$0.74
52-Week Range
$0.24
$2.93
Volume
4.03 million shs
Average Volume
1.72 million shs
Market Capitalization
$158.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75

Akebia Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
118.8% Upside
$1.75 Price Target
Short Interest
Healthy
2.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.17
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.59) to ($0.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

439th out of 1,030 stocks

Pharmaceutical Preparations Industry

219th out of 502 stocks


AKBA stock logo

About Akebia Therapeutics (NASDAQ:AKBA) Stock

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKBA Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Akebia Receives Interim Response From FDA To Appeal For Vadadustat
H.C. Wainwright Keeps Their Hold Rating on Akebia Therapeutics (AKBA)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Akebia Therapeutics Earnings Preview
See More Headlines
Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKBA Company Calendar

Last Earnings
11/04/2021
Today
2/02/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKBA
Employees
426
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.75
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$1.25
Forecasted Upside/Downside
+103.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-282,840,000.00
Pretax Margin
-52.42%

Debt

Sales & Book Value

Annual Sales
$213.58 million
Book Value
$0.44 per share

Miscellaneous

Free Float
178,590,000
Market Cap
$158.37 million
Optionable
Optionable
Beta
0.91

Key Executives

  • John P. ButlerJohn P. Butler
    President, Chief Executive Officer & Director
  • Michel DahanMichel Dahan
    Chief Operating Officer & Senior Vice President
  • David A. SpellmanDavid A. Spellman
    Treasurer, Chief Financial & Accounting Officer
  • Steven K. BurkeSteven K. Burke
    Chief Medical Officer & Senior Vice President
  • Michael Rabinowitz
    Vice President-Research













AKBA Stock - Frequently Asked Questions

Should I buy or sell Akebia Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AKBA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares.
View AKBA analyst ratings
or view top-rated stocks.

What is Akebia Therapeutics' stock price forecast for 2023?

6 analysts have issued 12 month target prices for Akebia Therapeutics' stock. Their AKBA share price forecasts range from $1.25 to $2.00. On average, they expect the company's share price to reach $1.75 in the next twelve months. This suggests a possible upside of 161.2% from the stock's current price.
View analysts price targets for AKBA
or view top-rated stocks among Wall Street analysts.

How have AKBA shares performed in 2023?

Akebia Therapeutics' stock was trading at $0.5770 at the beginning of the year. Since then, AKBA shares have increased by 16.1% and is now trading at $0.67.
View the best growth stocks for 2023 here
.

When is Akebia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our AKBA earnings forecast
.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.02. The biopharmaceutical company had revenue of $48.76 million for the quarter, compared to the consensus estimate of $50.09 million. Akebia Therapeutics had a negative trailing twelve-month return on equity of 315.92% and a negative net margin of 52.42%. During the same quarter last year, the company earned ($0.42) earnings per share.

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David A Spellman, Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau.
View institutional ownership trends
.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $0.67.

How much money does Akebia Therapeutics make?

Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $123.25 million and generates $213.58 million in revenue each year. The biopharmaceutical company earns $-282,840,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does Akebia Therapeutics have?

The company employs 426 workers across the globe.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099.

This page (NASDAQ:AKBA) was last updated on 2/2/2023 by MarketBeat.com Staff